Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | LSS | P48449 | 2/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8052861 | 0.99 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3SRD5A2HRH3 | |
| Hydrochloric Acid SCHEMBL9442703 | 0.84 | HRH3 (0.65) | HRH3TAAR1LSSMCHR1ACHE | |
| SCHEMBL3675147 | 0.83 | LSS (0.70) | SLC6A2SLC6A4SLC6A3SRD5A2LSS | |
| Hydrochloric Acid SCHEMBL8049750 | 0.82 | LSS (0.70) | SLC6A2SLC6A4SLC6A3SRD5A2LSS | |
| SCHEMBL3673292 | 0.81 | LSS (0.51) | SLC6A2SLC6A4SLC6A3SRD5A2HRH3 | |
| SCHEMBL25137173 | 0.80 | HRH3 (0.56) | HRH3TAAR1LSSMCHR1ACHE | |
| Hydrochloric Acid SCHEMBL8049541 | 0.80 | LSS (0.52) | SLC6A2SLC6A4SLC6A3SRD5A2HRH3 | |
| SCHEMBL8047821 | 0.80 | SRD5A2 (0.57) | SLC6A2SLC6A4SLC6A3SRD5A2HDAC1 | |
| SCHEMBL19389734 | 0.79 | LSS (0.58) | SRD5A2HRH3TAAR1LSSACHE | |
| Hydrochloric Acid SCHEMBL9148032 | 0.79 | SRD5A2 (0.55) | SLC6A2SLC6A4SLC6A3SRD5A2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0636367-B1 | Use of phenylalkylamines for producing cholesterol lowering agents | HOFFMANN LA ROCHE (CH) | 2000-03-29 | — | — | EP | claimed |
| EP-0636367-A1 | Use of phenylalkylamines for producing cholesterol lowering agents | F. HOFFMANN-LA ROCHE AG (CH) | 1995-02-01 | — | — | EP | claimed |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| WO-2010021681-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-02-25 | — | — | WO | disclosed |
| EP-0636367-B1 | Use of phenylalkylamines for producing cholesterol lowering agents | HOFFMANN LA ROCHE (CH) | 2000-03-29 | — | — | EP | disclosed |
| US-5637771-A | Compound useful for lowering cholesterol | HOFFMANN-LA ROCHE INC. (US) | 1997-06-10 | — | — | US | disclosed |
| US-5574071-A | ADMINISTERING PHENYLALKYLAMINO KETONES | HOFFMANN-LA ROCHE INC. (US) | 1996-11-12 | — | — | US | disclosed |
| US-5495048-A | ANTICHOLESTEROL AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | disclosed |
| EP-0636367-A1 | Use of phenylalkylamines for producing cholesterol lowering agents | F. HOFFMANN-LA ROCHE AG (CH) | 1995-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, RNASE1, EIF2AK2 | SLC6A2 4758/4885SLC6A4 4825/4885SLC6A3 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.